Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency
In present study were compared characteristics of rituximab produced by Hoffmann–La Roche (Mabtera®) and first domestic biosimilar Acellbia® from Biocad Company. Concentration of protein was measured using Bradford, s method. According to our results, protein concentration in formulations was the sa...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-12-01
|
| Series: | Onkogematologiâ |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/168 |